Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 4/2017

12.09.2016 | Original Article

18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience

verfasst von: Domenico Albano, Mattia Bertoli, Paola Ferro, Federico Fallanca, Luigi Gianolli, Maria Picchio, Raffaele Giubbini, Francesco Bertagna

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The role of 18F-FDG-PET/CT in evaluating gastric MALT lymphoma is still controversial. In the literature the detection rate of 18F-FDG-PET/CT in patients with gastric MALT lymphoma is variable, and the reason for this heterogeneity is not still clear. Our aim was to investigate the particular metabolic behavior of these lymphoma.

Materials and methods

Sixty-nine patients (26 female, 43 male) with histologically confirmed gastric MALT lymphoma who underwent a 18F-FDG-PET/CT for initial staging from two centers were included. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value (SUVmax), lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio and compared with Ann Arbor stage, epidemiological (age, sex), histological (presence of gastritis, ulcer, H. pylori infection, plasmacytic differentiation, Ki-67 index), and morphological (tumor size, superficial lesions or mass-forming) characteristics.

Results

Thirty-six patients (52 %) had positive PET/CT (average SUVmax was 9±6.7; lesion-to-liver SUVmax ratio 3.7±2.6, lesion-to-blood pool SUVmax ratio 4.8±3.3) at the corresponding gastric lesion; the remaining 33 were not 18F-FDG-avid. In the univariate analysis, 18F-FDG avidity was significantly associated with morphological features (mass forming p<0.001 and high maximum diameter p<0.001), Ann Arbor stage (p=0.010), and Ki67 index (p<0.001) and not correlated with age, sex, presence of gastritis, ulcer, Helicobacter pylori infection, and plasmacytic differentiation. In the multivariate analysis, the correlations with gross morphological appearance, Ann Arbor stage, and Ki-67 score were confirmed. SUVmax, lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio correlated significantly only with Ki67 index (p=0.047; p=0.012; p=0.042).

Conclusions

18F-FDG avidity was noted in 52 % of gastric MALT lymphoma and this avidity is correlated with gross morphological characteristics, tumor stage, and Ki-67 index. SUVmax, lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio are correlated only with Ki-67 index, and only lesion-to-liver SUVmax ratio was independently associated with Ki-67 score.
Literatur
1.
Zurück zum Zitat Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;50:1410–6.CrossRef Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;50:1410–6.CrossRef
2.
Zurück zum Zitat Jaffe ES, Harris NL, Stein H, Vardinam JW. Tumours of haematopoietic and lymphoid tissues: world health organization classification of tumours, pathology, and genetics. Lyon: IARC Press; 2001. Jaffe ES, Harris NL, Stein H, Vardinam JW. Tumours of haematopoietic and lymphoid tissues: world health organization classification of tumours, pathology, and genetics. Lyon: IARC Press; 2001.
3.
Zurück zum Zitat A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 1997;89:3909–18. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 1997;89:3909–18.
4.
Zurück zum Zitat Dreyling M, Thieblemont C, Gallamini A, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857–77.CrossRefPubMed Dreyling M, Thieblemont C, Gallamini A, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857–77.CrossRefPubMed
5.
Zurück zum Zitat Taal BG, Burgers JM, van Heerde P, Hart AA, Somers R. The clinical spectrum and treatment of primary non-Hodgkin’s lymphoma of the stomach. Ann Oncol. 1993;4:839–46. Taal BG, Burgers JM, van Heerde P, Hart AA, Somers R. The clinical spectrum and treatment of primary non-Hodgkin’s lymphoma of the stomach. Ann Oncol. 1993;4:839–46.
6.
Zurück zum Zitat Harris NL, Jaffe ES, Diebold J, et al. The world health organization classification of hematological malignancies report of the clinical advisory committee meeting, Arlie house Virginia, November 1997. Mod Pathol. 2000;13:193–207.CrossRefPubMed Harris NL, Jaffe ES, Diebold J, et al. The world health organization classification of hematological malignancies report of the clinical advisory committee meeting, Arlie house Virginia, November 1997. Mod Pathol. 2000;13:193–207.CrossRefPubMed
7.
Zurück zum Zitat Woehrer S, Strubel B, Chott A, Hoffmann M, Raderer M. Transmortation of MALT lymphoma to pure plasma cells histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma. 2005;46:1645–9.CrossRefPubMed Woehrer S, Strubel B, Chott A, Hoffmann M, Raderer M. Transmortation of MALT lymphoma to pure plasma cells histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma. 2005;46:1645–9.CrossRefPubMed
8.
Zurück zum Zitat Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.CrossRefPubMedPubMedCentral Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048–58.CrossRefPubMedPubMedCentral Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048–58.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol. 2007;17:190–7.CrossRefPubMed Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol. 2007;17:190–7.CrossRefPubMed
11.
Zurück zum Zitat Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4:5.PubMed Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4:5.PubMed
12.
Zurück zum Zitat Schwenzer NF, Pfannenberg AC. PET/CT, MR, and PET/MR in lymphoma and melanoma. Semin Nucl Med. 2015;45:322–31.CrossRefPubMed Schwenzer NF, Pfannenberg AC. PET/CT, MR, and PET/MR in lymphoma and melanoma. Semin Nucl Med. 2015;45:322–31.CrossRefPubMed
13.
Zurück zum Zitat Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi144–8. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi144–8.
15.
Zurück zum Zitat Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016;66:152–71.CrossRef Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016;66:152–71.CrossRef
16.
Zurück zum Zitat Treglia G, Zucca E, Sadeghi R, Cavalli F, Giovanella L, Ceriani L. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. Hematol Oncol. 2015;33:113–24.CrossRefPubMed Treglia G, Zucca E, Sadeghi R, Cavalli F, Giovanella L, Ceriani L. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. Hematol Oncol. 2015;33:113–24.CrossRefPubMed
18.
Zurück zum Zitat Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18–2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10:1185–9.CrossRefPubMed Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18–2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10:1185–9.CrossRefPubMed
19.
Zurück zum Zitat Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18FFluorodeoxyglucose positron emission tomography (18F-FDGPET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology. 2003;64:336–40.CrossRefPubMed Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18FFluorodeoxyglucose positron emission tomography (18F-FDGPET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology. 2003;64:336–40.CrossRefPubMed
20.
Zurück zum Zitat Ambrosini V, Rubello D, Castellucci P, et al. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur. 2006;9:37–40.PubMed Ambrosini V, Rubello D, Castellucci P, et al. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur. 2006;9:37–40.PubMed
21.
Zurück zum Zitat Fu L, Li H, Wang H, Xu B, Fan Y, Tian J. SUVmax/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma. PLoS One. 2012;7, e50914.CrossRefPubMedPubMedCentral Fu L, Li H, Wang H, Xu B, Fan Y, Tian J. SUVmax/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma. PLoS One. 2012;7, e50914.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Hirose Y, Kaida H, Ishibashi M, et al. Comparison between endoscopic macroscopic classification and F-18 FDG PET findings in gastric mucosa-associated lymphoid tissue lymphoma patients. Clin Nucl Med. 2012;37:152–7.CrossRefPubMed Hirose Y, Kaida H, Ishibashi M, et al. Comparison between endoscopic macroscopic classification and F-18 FDG PET findings in gastric mucosa-associated lymphoid tissue lymphoma patients. Clin Nucl Med. 2012;37:152–7.CrossRefPubMed
23.
Zurück zum Zitat Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol. 2010;28:57–61.PubMed Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol. 2010;28:57–61.PubMed
24.
Zurück zum Zitat Radan L, Fischer D, Bar-Shalom R, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging. 2008;35:1424–30.CrossRefPubMed Radan L, Fischer D, Bar-Shalom R, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging. 2008;35:1424–30.CrossRefPubMed
25.
Zurück zum Zitat Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79:205–9.CrossRefPubMed Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79:205–9.CrossRefPubMed
26.
Zurück zum Zitat Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005;16:473–80.CrossRefPubMed Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005;16:473–80.CrossRefPubMed
27.
Zurück zum Zitat Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.CrossRefPubMed Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.CrossRefPubMed
28.
Zurück zum Zitat Enomoto K, Hamada K, Inohara H, et al. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings. Ann Nucl Med. 2008;22:261–7.CrossRefPubMed Enomoto K, Hamada K, Inohara H, et al. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings. Ann Nucl Med. 2008;22:261–7.CrossRefPubMed
29.
Zurück zum Zitat Alinari L, Castellucci P, Elstrom R, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2006;47:2096–101.CrossRefPubMed Alinari L, Castellucci P, Elstrom R, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2006;47:2096–101.CrossRefPubMed
30.
Zurück zum Zitat Hoffmann M, Wöhrer S, Becherer A, et al. 18F-Fluoro-deoxyglucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol. 2006;17:1761–5.CrossRefPubMed Hoffmann M, Wöhrer S, Becherer A, et al. 18F-Fluoro-deoxyglucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol. 2006;17:1761–5.CrossRefPubMed
31.
Zurück zum Zitat Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluorodeoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175–83.CrossRefPubMed Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluorodeoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175–83.CrossRefPubMed
32.
Zurück zum Zitat Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157–64.CrossRefPubMed Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157–64.CrossRefPubMed
33.
Zurück zum Zitat Sharma P, Suman S, Singh H, et al. Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment. Leuk Lymphoma. 2013;54(5):951–8.CrossRefPubMed Sharma P, Suman S, Singh H, et al. Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment. Leuk Lymphoma. 2013;54(5):951–8.CrossRefPubMed
34.
Zurück zum Zitat Carrillo-Cruz E, Marin-Oyaga V, de la Cruz Vicente F, et al. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol. 2015;33(4):151–8.CrossRefPubMed Carrillo-Cruz E, Marin-Oyaga V, de la Cruz Vicente F, et al. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol. 2015;33(4):151–8.CrossRefPubMed
35.
Zurück zum Zitat Hwang JW, Jee SR, Lee SH, Kim JH, Seol SY, Lee SM. Efficacy of positron emission tomography/computed tomography in gastric mucosa-associated lymphoid tissue lymphoma. Korean J Gastroenterol. 2016;67:183–8.CrossRefPubMed Hwang JW, Jee SR, Lee SH, Kim JH, Seol SY, Lee SM. Efficacy of positron emission tomography/computed tomography in gastric mucosa-associated lymphoid tissue lymphoma. Korean J Gastroenterol. 2016;67:183–8.CrossRefPubMed
36.
Zurück zum Zitat Park SH, Lee JJ, Kim HO, et al. 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement. Leuk Lymphoma. 2015;56(12):3288–94.CrossRefPubMed Park SH, Lee JJ, Kim HO, et al. 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement. Leuk Lymphoma. 2015;56(12):3288–94.CrossRefPubMed
37.
Zurück zum Zitat Tsai HK, Li S, Ng AK, Silver B, Stevenson MA, Mauch PM. Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphiod tissue lymphoma. Ann Oncol. 2007;18:672–8.CrossRefPubMed Tsai HK, Li S, Ng AK, Silver B, Stevenson MA, Mauch PM. Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphiod tissue lymphoma. Ann Oncol. 2007;18:672–8.CrossRefPubMed
38.
Zurück zum Zitat Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–73.PubMedPubMedCentral Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–73.PubMedPubMedCentral
39.
Zurück zum Zitat Koo HR, Parl JS, Kang KW, Han W, Park IA, Moon WK. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur Radiol. 2015;25:3314–21.CrossRefPubMed Koo HR, Parl JS, Kang KW, Han W, Park IA, Moon WK. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur Radiol. 2015;25:3314–21.CrossRefPubMed
40.
Zurück zum Zitat Park S, Lee E, Rhee S, et al. Correlation between semi-quantitative 18F-FDG PET/CT parameters and Ki-67 expression in small cell lung cancer. Nucl Med Mol Imaging. 2016;50:24–30.CrossRefPubMed Park S, Lee E, Rhee S, et al. Correlation between semi-quantitative 18F-FDG PET/CT parameters and Ki-67 expression in small cell lung cancer. Nucl Med Mol Imaging. 2016;50:24–30.CrossRefPubMed
41.
Zurück zum Zitat Nakamura S, Akazawa K, Yao T, Tsuneyoshi M. A clinicopathologic study of 233 cases with special reference to evaluation with the MIB-1 index. Cancer. 1995;76:1313–24.CrossRefPubMed Nakamura S, Akazawa K, Yao T, Tsuneyoshi M. A clinicopathologic study of 233 cases with special reference to evaluation with the MIB-1 index. Cancer. 1995;76:1313–24.CrossRefPubMed
42.
Zurück zum Zitat Watanabe Y, Suefuji H, Hirose Y, et al. 18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential. Int J Hematol. 2013;97:43–9.CrossRefPubMed Watanabe Y, Suefuji H, Hirose Y, et al. 18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential. Int J Hematol. 2013;97:43–9.CrossRefPubMed
Metadaten
Titel
18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience
verfasst von
Domenico Albano
Mattia Bertoli
Paola Ferro
Federico Fallanca
Luigi Gianolli
Maria Picchio
Raffaele Giubbini
Francesco Bertagna
Publikationsdatum
12.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3518-y

Weitere Artikel der Ausgabe 4/2017

European Journal of Nuclear Medicine and Molecular Imaging 4/2017 Zur Ausgabe